MENU
+Compare
ENTX
Stock ticker: NASDAQ
AS OF
Aug 8 closing price
Price
$1.82
Change
+$0.02 (+1.11%)
Capitalization
82.72M

ENTX Entera Bio Ltd Forecast, Technical & Fundamental Analysis

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins... Show more

ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ENTX with price predictions
Aug 08, 2025

ENTX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on August 07, 2025

ENTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 48 cases where ENTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for ENTX crossed bullishly above the 50-day moving average on July 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTX advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTX as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ENTX turned negative on August 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

ENTX moved below its 50-day moving average on August 07, 2025 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for ENTX moved below the 200-day moving average on July 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ENTX entered a downward trend on July 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ENTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.794) is normal, around the industry mean (18.702). P/E Ratio (0.000) is within average values for comparable stocks, (54.306). ENTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.011). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (287.256).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ENTX is expected to report earnings to rise 166.67% to -15 cents per share on November 06

Entera Bio Ltd ENTX Stock Earnings Reports
Q3'25
Est.
$-0.16
Q1'25
Beat
by $0.01
Q4'24
Est.
$-0.06
Q3'24
Missed
by $0.03
Q2'24
Est.
$-0.06
The last earnings report on May 09 showed earnings per share of -5 cents, beating the estimate of -7 cents. With 114.85K shares outstanding, the current market capitalization sits at 82.72M.
A.I. Advisor
published General Information

General Information

a manufacturer of flu medicines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Minrav Building - Fifth Floor
Phone
+972 25327151
Employees
19
Web
https://www.enterabio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BKRIF14.750.25
+1.69%
Bank Ireland Group PLC
CFXTF0.25N/A
N/A
Conifex Timber Inc.
LDGYY20.52N/A
N/A
Landis Gyr Group AG
FPLSF11.09-0.21
-1.86%
5N Plus, Inc.

ENTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTX has been loosely correlated with STOK. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTX jumps, then STOK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
+1.11%
STOK - ENTX
33%
Loosely correlated
-1.13%
JSPR - ENTX
32%
Poorly correlated
-10.26%
OPORF - ENTX
31%
Poorly correlated
N/A
DNLI - ENTX
31%
Poorly correlated
-1.90%
IMNM - ENTX
30%
Poorly correlated
-1.82%
More

Groups containing ENTX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
+1.11%
flu medicines
theme (2 stocks)
50%
Loosely correlated
-0.09%
middle east
theme (68 stocks)
17%
Poorly correlated
+0.01%
pharmaceuticals
theme (152 stocks)
13%
Poorly correlated
+0.66%